The goal of the Career Development Program of the M. D. Anderson Cancer Center Prostate SPORE is to develop a cadre of investigators dedicated to translational studies in human prostate cancer. The program will (1) recruit innovative entry-level scientists into the Prostate SPORE to enhance its overall translational research capability and bring new techniques and talent to our SPORE program, (2) help these individuals develop the intellectual and technical skills required to be productive investigators in translational prostate cancer research, and (3) teach these individuals basic principles of cancer biology not commonly included in clinical training or PhD degree programs. The unique educational environment that exists at M. D. Anderson will ensure that these goals will be met. At least three Career Development awardees will be selected annually from qualified candidates within and outside M. D. Anderson Cancer Center. Awardees will be selected from the pool of candidates who respond to a SPORE solicitation based on objective criteria established by the Program Director and Co-Director in collaboration with the Principal Investigator and Co- Principal Investigator. Applications will be solicited and reviewed annually, and announcements for applications will be published in appropriate journals and on the SPORE web site as well as mailed to selected academic centers. The awardees'mentors have been selected from a large, diverse group of laboratory scientists and clinicians at M. D. Anderson based on their interest in translational science and skill as educators. The mentorship training will include principles of cancer biology, scientific methods, statistical analysis, biomedical communications, and strategies necessary to become successful in translational prostate cancer research. The program will be evaluated annually, and modifications in the selection process or training will be made when appropriate. Nine Career Development awards were funded by the initial SPORE in Prostate Cancer. Investigators receiving Career Development Awards reported 96 publications. A total of 25 externally reviewed grants were funded. Of note, one investigator (Dr. Jeri Kim) is a collaborator in Project 5 and the Specimen Core in this new M. D. Anderson Cancer Center Prostate SPORE proposal, reflecting the important role of the Career Development Program in identifying investigators with the potential to make significant contributions in translational prostate cancer research.
The goal of the Career Development Program of the M. D. Anderson Cancer Center Prostate SPORE is to develop a cadre of investigators dedicated to translational studies in human prostate cancer by recruiting innovative entry-level scientists to enhance, the SPORE's overall translational research capability, helping these individuals develop intellectual and technical skills required to be productive investigators, and teaching these individuals basic principles of cancer biology.
|Wang, Hong; Yang, Xu; Liu, Anna et al. (2018) ?-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. Carcinogenesis 39:158-169|
|Velazquez-Torres, Guermarie; Shoshan, Einav; Ivan, Cristina et al. (2018) A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun 9:461|
|Zanoaga, Oana; Jurj, Ancuta; Raduly, Lajos et al. (2018) Implications of dietary ?-3 and ?-6 polyunsaturated fatty acids in breast cancer. Exp Ther Med 15:1167-1176|
|Zhang, Wei; Liu, Bo; Wu, Wenhui et al. (2018) Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24:696-707|
|Monroig-Bosque, Paloma Del C; Shah, Maitri Y; Fu, Xiao et al. (2018) OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. Sci Rep 8:13106|
|Basourakos, Spyridon P; Davis, John W; Chapin, Brian F et al. (2018) Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int 121:69-76|
|Pan, Tianhong; Lin, Song-Chang; Yu, Kai-Jie et al. (2018) BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia 20:32-43|
|Yu-Lee, Li-Yuan; Yu, Guoyu; Lee, Yu-Chen et al. (2018) Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGF?RIII-p38MAPK-pS249/T252RB Pathway. Cancer Res 78:2911-2924|
|Luo, Yong; Azad, Abul Kalam; Karanika, Styliani et al. (2018) Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer 142:2163-2174|
|Soundararajan, Rama; Aparicio, Ana M; Logothetis, Christopher J et al. (2018) Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers. Front Oncol 8:69|
Showing the most recent 10 out of 217 publications